65 related articles for article (PubMed ID: 35617682)
1. Low-dose IL-2 treatment confers anti-inflammatory effect against subarachnoid hemorrhage in mice.
Liu J; Qi B; Ye Y; Shen Y; Lin Y; Chen Y; Ding S; Ma J; Chen S
Heliyon; 2024 May; 10(9):e30013. PubMed ID: 38742061
[TBL] [Abstract][Full Text] [Related]
2. An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells.
Jamison BL; Lawrance M; Wang CJ; DeBerg HA; Sansom DM; Gavin MA; Walker LSK; Campbell DJ
bioRxiv; 2023 Dec; ():. PubMed ID: 38106196
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.
Wobma H; Kapadia M; Kim HT; Alvarez-Calderon F; Baumeister SHC; Duncan C; Forrest S; Gorfinkel L; Huang J; Lehmann LE; Li H; Schwartz M; Koreth J; Ritz J; Kean LS; Whangbo JS
Blood Adv; 2023 Aug; 7(16):4647-4657. PubMed ID: 37603347
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME; Sahin D; Karakus U; Boyman O
EBioMedicine; 2023 Apr; 90():104539. PubMed ID: 37004361
[TBL] [Abstract][Full Text] [Related]
5. Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.
Kostareva I; Kirgizov K; Machneva E; Ustyuzhanina N; Nifantiev N; Skvortsova Y; Shubina I; Reshetnikova V; Valiev T; Varfolomeeva S; Kiselevskiy M
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145321
[TBL] [Abstract][Full Text] [Related]
6. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
Salhotra A; Falk L; Park G; Sandhu K; Ali H; Modi B; Hui S; Nakamura R
Expert Rev Clin Immunol; 2024 Feb; 20(2):169-184. PubMed ID: 37921226
[TBL] [Abstract][Full Text] [Related]
7. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
[TBL] [Abstract][Full Text] [Related]
8. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
Kim HT; Koreth J; Whangbo J; Nikiforow S; Reynolds CG; Stowe P; Ho VT; Cutler C; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2022 Aug; 6(15):4392-4402. PubMed ID: 35617682
[TBL] [Abstract][Full Text] [Related]
9. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
Whangbo JS; Kim HT; Nikiforow S; Koreth J; Alho AC; Falahee B; Kim S; Dusenbury K; Fields MJ; Reynolds CG; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2019 Apr; 3(7):984-994. PubMed ID: 30936059
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
